RareResearch.AI
← Back to atlas

F264L

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorial
PhenylalanineLeucine at position 264 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Phenylalanine → Leucine at position 264 in N-terminal cytoplasmic domain. ClinVar Conflicting including Wolfram-like syndrome. AlphaMissense 0.29 (below threshold) — AM under-call. DynaMut2 ΔΔG +0.19 kcal/mol (stabilising). pLDDT 47 — Category 5 IDR territory.

Interactive 3D Structure

Wild-type reference
Wild-type F264 — hydrogen bond to S261
Fullscreen ↗
DynaMut2 mutant · F264L
Mutant L264 — hydrogen bond to S261 lost (2 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

2 lost1 gained2 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondS261S261Preserved
Polar contactS261Lost
Polar contactS262S262Preserved
Polar contactQ266Gained
HydrophobicI259Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
0.19kcal/mol
Stabilising — mild
AlphaMissense
0.287
LBen
AlphaFold pLDDT
47
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion
ΔΔG confidence: Reduced confidence · Cytoplasmic
  • pLDDT 47.03 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsWFS1-related disorder; Wolfram-like syndrome
InheritanceWFS1-related disorder + Wolfram-like syndrome documented.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0011%
cDNA changec.792C>G
ClinVar accessionVCV000504707
Last evaluated2025/06/12 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for WFS1-related spectrum (unresolved mode) (dominant or recessive); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Cataract 41 (autosomal dominant, OMIM 116400); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). ClinVar records this under a WFS1-spectrum label that spans both disease families — recessive Wolfram syndrome (biallelic) and the dominant WFS1-related disorders. The label does not resolve which applies, and it is not a severity statement.

  • WFS1-related spectrum (unresolved mode)dominant or recessivesubmitted as: WFS1-related disorder
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1; Wolfram syndrome 1
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0011% · 17 / 1,613,366 alleles
Homozygotes
0
Highest-frequency population
African / African American · AF 0.021%

Highest in African / African American: AF 0.021% (16 of 75,036 alleles), 20.2x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
African / African American0.021%16 / 75,0360~1 in 2340
Remaining individuals · under-sampled0.0016%1 / 62,4960

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 264 sits in wolframin's N-terminal cytoplasmic domain at the boundary of the IDR. pLDDT of 47 is BELOW the 50 threshold — the Atlas formally classifies this position as Category 5 (IDR exclusion). DynaMut2 predictions in this region are not fully trustworthy.

Neighbors: LEU263 (2.5 Å), LEU265 (2.5 Å), SER261 (4.1 Å). The neighbor sparsity is itself an IDR signature.

AlphaMissense's 0.29 is below threshold. The Conflicting ClinVar classifications and the IDR localization together flag this variant as one where computational drug discovery should pause for wet-lab characterization.

Amino-acid chemistry
Phenylalanine (F) → Leucine (L) — aromatic hydrophobic replaced by branched aliphatic hydrophobic. Aromatic π-system lost.
Position in the protein
N-terminal cytoplasmic domain · position 264 in a borderline-IDR region (pLDDT 47).

Druggability Assessment

Category 5 — IDR Exclusion (borderline). pLDDT 47 below the 50 threshold. AlphaMissense 0.29 below threshold. DynaMut2 prediction not trustworthy.

The Atlas routes Category 5 variants to wet-lab characterization rather than computational drug discovery.

Why this matters

F264L is the latest Category 5 IDR-region variant in the Atlas. Wet-lab validation required before therapeutic strategy is set.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the F264L PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download F264L PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A